Genome Editing Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Genome Editing stocks.

Genome Editing Stocks Recent News

Date Stock Title
Nov 21 CRSP CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)
Nov 20 CRSP CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
Nov 20 EDIT Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)
Nov 20 CRSP CRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right Now
Nov 19 NTLA Intellia Therapeutics Announces Promising CRISPR Therapy Results
Nov 19 NTLA ReCode to secure funds for cystic fibrosis gene correction treatments
Nov 19 NTLA Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo
Nov 19 ABEO ABEO: FDA Accepts BLA Re-Submission for Pz-cel; PDUFA Date of April 29, 2025; Raising Valuation to $9.50…
Nov 19 NTLA Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)
Nov 18 MGX What Makes Metagenomi (MGX) a New Buy Stock
Nov 18 NTLA Intellia’s gene editing therapy shows early potential in rare heart condition
Nov 18 NTLA CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
Nov 18 CRSP CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest
Nov 17 CRSP CRISPR Therapeutics AG (CRSP): Among ARK Invest’s Top Stock Picks for 2024
Nov 16 NTLA Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
Nov 16 CRSP 2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
Nov 15 CRSP CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)
Nov 15 MGX Metagenomi Third Quarter 2024 Earnings: US$0.51 loss per share (vs US$3.33 loss in 3Q 2023)
Nov 15 DTIL Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
Nov 15 CRSP Where Will CRISPR Therapeutics Be in 3 Years?
Genome Editing

Genome editing, or genome engineering, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike early genetic engineering techniques that randomly inserts genetic material into a host genome, genome editing targets the insertions to site specific locations.
In 2018, the common methods for such editing use engineered nucleases, or "molecular scissors". These nucleases create site-specific double-strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are repaired through nonhomologous end-joining (NHEJ) or homologous recombination (HR), resulting in targeted mutations ('edits').
As of 2015 four families of engineered nucleases were used: meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector-based nucleases (TALEN), and the clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) system. Nine genome editors were available as of 2017.Genome editing with engineered nucleases, i.e. all three major classes of these enzymes—zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and engineered meganucleases—were selected by Nature Methods as the 2011 Method of the Year. The CRISPR-Cas system was selected by Science as 2015 Breakthrough of the Year.

Browse All Tags